Europe — EMA
Granisetron Sigillata
Granisetron Sigillata is an oral 5‑HT3 antagonist used to prevent chemotherapy, radiotherapy, and postoperative nausea and vomiting. Find indications, side effects, and safety information.
Request sourcing
What is Granisetron?
Granisetron Sigillata is an oral tablet containing the active ingredient granisetron; the strength is not specified. It is a prescription‑only medication marketed in the European Union and belongs to the 5‑HT3 receptor antagonist class, used as an antiemetic to manage nausea and vomiting. It works by selectively blocking peripheral and central serotonin (5‑HT3) receptors, thereby reducing the stimulus for emesis.
What is Granisetron used for?
Granisetron Sigillata is indicated for the prevention and treatment of nausea and vomiting associated with several medical procedures.
- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Prevention of radiotherapy‑induced nausea and vomiting (RINV). - Prevention of postoperative nausea and vomiting (PONV) following surgery. - Adjunct therapy for nausea related to other emetogenic stimuli when other measures are insufficient. - Use in patients who require a selective 5‑HT3 antagonist with oral dosing convenience.
What are the side effects of Granisetron?
Granisetron Sigillata may cause side effects; they are categorized by frequency and severity.
Common: - Headache. - Constipation or mild abdominal discomfort. - Fatigue or drowsiness. - Dizziness or light‑headed feeling.
Serious: - Severe allergic reaction such as rash, itching, swelling, or difficulty breathing. - Cardiac arrhythmia or prolonged QT interval. - Persistent severe constipation or intestinal blockage. - Signs of serotonin syndrome when combined with serotonergic agents.
What precautions apply to Granisetron?
When prescribing Granisetron Sigillata, clinicians should consider several precautionary measures to ensure safe use.
- Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use caution in patients with known cardiac conduction disorders or prolonged QT interval. - Evaluate renal or hepatic impairment, as dose adjustment may be required. - Monitor for signs of constipation, especially in patients with gastrointestinal motility disorders. - Discuss pregnancy and breastfeeding status; safety data are limited. - Review concomitant use of other antiemetics to avoid overlapping effects.
What does Granisetron interact with?
Granisetron Sigillata can interact with other medications; some combinations should be avoided while others require careful monitoring.
Avoid: - Other serotonergic drugs (e.g., SSRIs, SNRIs, tramadol) that may increase risk of serotonin syndrome. - Medications known to prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics). - Strong CYP3A4 inhibitors if the product formulation relies on this pathway for metabolism.
Use with caution: - CYP3A4 inducers (e.g., rifampin, carbamazepine) which may reduce granisetron exposure. - Other antiemetics that act on different receptors, to avoid additive central nervous system effects. - Diuretics or laxatives, as they may exacerbate constipation when combined with granisetron.
